The role of transcatheter aortic valve replacement in the patients with severe aortic stenosis requiring major non-cardiac surgery

  • Taishi Okuno
  • Kazuyuki Yahagi
  • Yu Horiuchi
  • Yu Sato
  • Tetsu Tanaka
  • Keita Koseki
  • Akira Osanai
  • Motoi Yokozuka
  • Sumio Miura
  • Kengo TanabeEmail author
Original Article


Severe aortic stenosis (AS) is considered as an independent risk factor for perioperative cardiac complications of non-cardiac surgery. Surgical aortic valve replacement should be considered before non-cardiac surgery in patients with symptomatic severe AS. However, recently, transcatheter aortic valve replacement (TAVR) has emerged as an alternative approach for selected AS patients. We sought to determine the safety and efficacy of TAVR in preparation for major non-cardiac surgery. From our retrospective database, seven patients who underwent TAVR in preparation for major non-cardiac surgery were identified, and their clinical and hemodynamic data were collected. After TAVR, a significant reduction in the mean transaortic pressure gradient from 54.0 (Interquartile range (IQR) 47.5–64.5) to 18.0 (IQR 12.5–19.0) mmHg (p = 0.016) and an increase in the calculated aortic valve area from 0.6 (IQR 0.6–0.7) to 1.3 (IQR 1.1–1.5) cm2 (p = 0.022) were noted. Non-cardiac surgery included lung segmentectomy and lymph node dissection, lung lobectomy, ileocecal resection, partial colectomy, partial nephrectomy, nephroureterectomy, laparoscopic nephrectomy, and laparoscopic nephroureterectomy. All the initial non-cardiac surgeries were performed without cardiac complications, under general anesthesia, 37 (IQR 32–74) days after TAVR. Two of the patients eventually needed additional non-cardiac surgery, which was performed uneventfully without the need for additional AS treatment. TAVR was an effective and safe procedure that might reduce the risk of general anesthesia and major non-cardiac surgery in severe AS.


Valvular heart disease Aortic valve stenosis Transcatheter aortic valve replacement Non-cardiac surgery 



Aortic stenosis


Balloon aortic valvuloplasty


Brain natriuretic peptide


Double antiplatelet therapy


Ejection fraction


Interquartile range


Surgical aortic valve replacement


Society of Thoracic Surgeons


Transcatheter aortic valve replacement


Compliance with ethical standards

Conflict of interest

Dr. Tanabe receives honoraria from Edwards Lifesciences, and Medtronic. Dr. Yokozuka receives honoraria from Edwards Lifesciences. Other authors report no conflicts of interest.


  1. 1.
    Kertai MD, Bountioukos M, Boersma E, Bax JJ, Thomson IR, Sozzi F, et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. Am J Med. 2004;116:8–13.CrossRefGoogle Scholar
  2. 2.
    Torsher LC, Shub C, Rettke SR, Brown DL. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. 1998;81:448–52.CrossRefGoogle Scholar
  3. 3.
    Leibowitz D, Rivkin G, Schiffman J, Rott D, Weiss AT, Mattan Y, et al. Effect of severe aortic stenosis on the outcome in elderly patients undergoing repair of hip fracture. Gerontology. 2009;55:303–6.CrossRefGoogle Scholar
  4. 4.
    Tashiro T, Pislaru SV, Blustin JM, Nkomo VT, Abel MD, Scott CG, et al. Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice. Eur Heart J. 2014;35:2372–81.CrossRefGoogle Scholar
  5. 5.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–185.CrossRefGoogle Scholar
  6. 6.
    Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.CrossRefGoogle Scholar
  7. 7.
    Suzuki S, Usui A, Yoshida K, Matsuura A, Ichihara T, Ueda Y. Effect of cardiopulmonary bypass on cancer prognosis. Asian Cardiovasc Thorac Ann. 2010;18:536–40.CrossRefGoogle Scholar
  8. 8.
    Yamamoto S, Yoshimasu T, Nishimura Y, Uchita S, Toguchi K, Honda K, et al. In vitro evaluation of the effect of cardiac surgery on cancer cell proliferation. Ann Thorac Cardiovasc Surg. 2011;17:260–6.CrossRefGoogle Scholar
  9. 9.
    Pinto CA, Marcella S, August DA, Holland B, Kostis JB, Demissie K. Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study. BMC Cancer. 2013;13:519.CrossRefGoogle Scholar
  10. 10.
    Mistiaen WP, Van Cauwelaert P, Muylaert P, Wuyts F, Harrisson F, Bortier H. Effect of prior malignancy on survival after cardiac surgery. Ann Thorac Surg. 2004;77:1593–7 (discussion 1597).CrossRefGoogle Scholar
  11. 11.
    Nardi P, Pellegrino A, Pugliese M, Bovio E, Chiariello L, Ruvolo G. Cardiac surgery with extracorporeal circulation and concomitant malignancy: early and long-term results. J Cardiovasc Med (Hagerstown). 2016;17:152–9.CrossRefGoogle Scholar
  12. 12.
    Hayes SN, Holmes DR Jr, Nishimura RA, Reeder GS. Palliative percutaneous aortic balloon valvuloplasty before noncardiac operations and invasive diagnostic procedures. Mayo Clin Proc. 1989;64:753–7.CrossRefGoogle Scholar
  13. 13.
    Roth RB, Palacios IF, Block PC. Percutaneous aortic balloon valvuloplasty: its role in the management of patients with aortic stenosis requiring major noncardiac surgery. J Am Coll Cardiol. 1989;13:1039–41.CrossRefGoogle Scholar
  14. 14.
    Litvack F, Jakubowski AT, Buchbinder NA, Eigler N. Lack of sustained clinical improvement in an elderly population after percutaneous aortic valvuloplasty. Am J Cardiol. 1988;62:270–5.CrossRefGoogle Scholar
  15. 15.
    Nishimura RA, Holmes DR Jr, Reeder GS. Percutaneous balloon valvuloplasty. Mayo Clin Proc. 1990;65:198–220.CrossRefGoogle Scholar
  16. 16.
    Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation. 1991;84:2383–97.CrossRefGoogle Scholar
  17. 17.
    Lieberman EB, Bashore TM, Hermiller JB, Wilson JS, Pieper KS, Keeler GP, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522–8.CrossRefGoogle Scholar
  18. 18.
    Badheka AO, Patel NJ, Singh V, Shah N, Chothani A, Mehta K, et al. Percutaneous aortic balloon valvotomy in the United States: a 13-year perspective. Am J Med. 2014;127(744–753):e743.Google Scholar
  19. 19.
    Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefGoogle Scholar
  20. 20.
    Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.CrossRefGoogle Scholar
  21. 21.
    Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.CrossRefGoogle Scholar
  22. 22.
    Tajima K, Yamamoto F, Kawazoe K, Nakatani I, Sakai H, Abe T, et al. Cardiopulmonary bypass and cellular immunity: changes in lymphocyte subsets and natural killer cell activity. Ann Thorac Surg. 1993;55:625–30.CrossRefGoogle Scholar
  23. 23.
    Horiuchi Y, Izumo M, Kusuhara T, Yokozuka M, Taketani T, Tanabe K. Combined transcatheter aortic valve implantation and type II endoleak repair after endovascular repair for abdominal aortic aneurysm. Cardiovasc Interv Ther. 2017;32:304–7.CrossRefGoogle Scholar
  24. 24.
    Tanaka T, Yahagi K, Okuno T, Horiuchi Y, Kusuhara T, Yokozuka M, et al. Transcatheter aortic valve implantation in a patient with severe aortic valve stenosis, colon cancer, and obstructive ileus: a case report. J Cardiol Cases. 2018;17:163–6.CrossRefGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2019

Authors and Affiliations

  • Taishi Okuno
    • 1
  • Kazuyuki Yahagi
    • 1
  • Yu Horiuchi
    • 1
  • Yu Sato
    • 1
  • Tetsu Tanaka
    • 1
  • Keita Koseki
    • 1
  • Akira Osanai
    • 2
  • Motoi Yokozuka
    • 3
  • Sumio Miura
    • 2
  • Kengo Tanabe
    • 1
    Email author
  1. 1.Division of CardiologyMitsui Memorial HospitalTokyoJapan
  2. 2.Division of Cardiovascular SurgeryMitsui Memorial HospitalTokyoJapan
  3. 3.Division of AnesthesiaMitsui Memorial HospitalTokyoJapan

Personalised recommendations